Moreover, another novel approach to individualized therapy in breast cancer patients using antibody-drug conjugates such as Trastuzumab Deruxtecan and Sacituzumab Govitecan has proven to significantly improve progression-free survival (PFS) and OS not only in patients with HER2 (Human Epidermal Growth Factor Receptor 2) positive but also with triple negative advanced breast cancer [10]. This evidence concerns the gene ERBB2 and breast carcinoma.